{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T15:58:56Z","timestamp":1790611136042,"version":"4.1.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s12325-026-03707-z","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T08:11:50Z","timestamp":1785226310000},"page":"4913-4935","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World PSA Response and Overall Survival Among Men with mCSPC Receiving Apalutamide Versus Darolutamide (Both Without Docetaxel) in the US"],"prefix":"10.1007","volume":"43","author":[{"given":"Mehmet A.","family":"Bilen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mukul","family":"Singhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Pilon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney D.","family":"Longfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Lowentritt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"key":"3707_CR1","unstructured":"National Cancer Institute Surveillance, Epidemiology, and End Results Program. Cancer stat facts: prostate cancer 2025. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/prost.html."},{"issue":"1","key":"3707_CR2","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s11934-025-01272-6","volume":"26","author":"SP Troy","year":"2025","unstructured":"Troy SP, Jakubowski CD, Gartrell BA. Packing the punch: current and emerging treatment strategies in metastatic castration-sensitive prostate cancer. Curr Urol Rep. 2025;26(1):50.","journal-title":"Curr Urol Rep"},{"key":"3707_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/ph17030351","author":"A Bernal","year":"2024","unstructured":"Bernal A, Bechler AJ, Mohan K, Rizzino A, Mathew G. The current therapeutic landscape for metastatic prostate cancer. Pharmaceuticals (Basel). 2024. https:\/\/doi.org\/10.3390\/ph17030351.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"1","key":"3707_CR4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1903307","volume":"381","author":"KN Chi","year":"2019","unstructured":"Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med. 2019;381(1):13\u201324.","journal-title":"N Engl J Med"},{"key":"3707_CR5","unstructured":"US Food & Drug Administration. FDA approves apalutamide for metastatic castration-sensitive prostate cancer 2019. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-apalutamide-metastatic-castration-sensitive-prostate-cancer."},{"issue":"20","key":"3707_CR6","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1200\/JCO.20.03488","volume":"39","author":"KN Chi","year":"2021","unstructured":"Chi KN, Chowdhury S, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, et al. Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study. J Clin Oncol. 2021;39(20):2294\u2013303.","journal-title":"J Clin Oncol"},{"key":"3707_CR7","unstructured":"US Food & Drug Administration. FDA approves darolutamide tablets for metastatic hormone-sensitive prostate cancer 2022. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-darolutamide-tablets-metastatic-hormone-sensitive-prostate-cancer."},{"issue":"12","key":"3707_CR8","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","volume":"386","author":"MR Smith","year":"2022","unstructured":"Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med. 2022;386(12):1132\u201342.","journal-title":"N Engl J Med"},{"key":"3707_CR9","unstructured":"US Food & Drug Administration. FDA approves darolutamide for metastatic castration-sensitive prostate cancer 2025. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-darolutamide-metastatic-castration-sensitive-prostate-cancer."},{"issue":"36","key":"3707_CR10","doi-asserted-by":"publisher","first-page":"4271","DOI":"10.1200\/JCO-24-01798","volume":"42","author":"F Saad","year":"2024","unstructured":"Saad F, Vjaters E, Shore N, Olmos D, Xing N, Pereira de Santana Gomes AJ, et al. Darolutamide in combination with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer from the phase III ARANOTE trial. J Clin Oncol. 2024;42(36):4271\u201381.","journal-title":"J Clin Oncol"},{"issue":"5","key":"3707_CR11","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.annonc.2023.02.009","volume":"34","author":"S Chowdhury","year":"2023","unstructured":"Chowdhury S, Bjartell A, Agarwal N, Chung BH, Given RW, Pereira de Santana Gomes AJ, et al. Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer. Ann Oncol. 2023;34(5):477\u201385.","journal-title":"Ann Oncol"},{"key":"3707_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2025.06.010","author":"F Saad","year":"2025","unstructured":"Saad F, Briganti A, Haresh KP, Vjaters E, Olmos D, Littleton N, et al. A deep prostate-specific antigen response to darolutamide plus androgen deprivation therapy is associated with better clinical outcomes in the phase 3 ARANOTE trial in patients with metastatic hormone-sensitive prostate cancer. Eur Urol Oncol. 2025. https:\/\/doi.org\/10.1016\/j.euo.2025.06.010.","journal-title":"Eur Urol Oncol"},{"issue":"7","key":"3707_CR13","doi-asserted-by":"publisher","first-page":"3437","DOI":"10.1007\/s12325-025-03207-6","volume":"42","author":"MA Bilen","year":"2025","unstructured":"Bilen MA, Lowentritt B, Khilfeh I, Rossi C, Du S, Kinkead F, et al. Overall survival with apalutamide versus enzalutamide in metastatic castration-sensitive prostate cancer. Adv Ther. 2025;42(7):3437\u201354.","journal-title":"Adv Ther"},{"issue":"2","key":"3707_CR14","first-page":"15","volume":"23","author":"G Brown","year":"2024","unstructured":"Brown G, Khilfeh I, Rossi C. A comparison of prostate-specific antigen response in patients with metastatic castration-sensitive prostate cancer initiated on apalutamide versus abiraterone acetate in linked clinical and claims databases. Rev Urol. 2024;23(2):15\u201327.","journal-title":"Rev Urol"},{"issue":"7","key":"3707_CR15","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2025-0023","volume":"14","author":"B Lowentritt","year":"2025","unstructured":"Lowentritt B, Bilen MA, Khilfeh I, Rossi C, Du S, Kinkead F, et al. Overall survival in patients with metastatic castration-sensitive prostate cancer treated with apalutamide versus abiraterone acetate: a head-to-head analysis of real-world patients in the USA. J Comp Eff Res. 2025;14(7):e250023.","journal-title":"J Comp Eff Res"},{"issue":"2","key":"3707_CR16","first-page":"29","volume":"23","author":"B Lowentritt","year":"2024","unstructured":"Lowentritt B, Khilfeh I, Pilon D, Du S, Rossi C, Kinkead F, et al. Real-world comparison of deep prostate-specific antigen response in patients with metastatic castration-sensitive prostate cancer treated with apalutamide or enzalutamide. Rev Urol. 2024;23(2):29\u201340.","journal-title":"Rev Urol"},{"key":"3707_CR17","unstructured":"Komodo Health Inc. Komodo Mortality Data Version 23.8 User Guide."},{"issue":"4","key":"3707_CR18","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1080\/03007995.2021.1879753","volume":"37","author":"SJ Freedland","year":"2021","unstructured":"Freedland SJ, Ke X, Lafeuille MH, Romdhani H, Kinkead F, Lefebvre P, et al. Identification of patients with metastatic castration-sensitive or metastatic castration-resistant prostate cancer using administrative health claims and laboratory data. Curr Med Res Opin. 2021;37(4):609\u201322.","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"3707_CR19","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","volume":"46","author":"PC Austin","year":"2011","unstructured":"Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar Behav Res. 2011;46(3):399\u2013424.","journal-title":"Multivar Behav Res"},{"issue":"25","key":"3707_CR20","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.3697","volume":"28","author":"PC Austin","year":"2009","unstructured":"Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28(25):3083\u2013107.","journal-title":"Stat Med"},{"issue":"3","key":"3707_CR21","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1093\/ndt\/gfz208","volume":"35","author":"TT Jansz","year":"2020","unstructured":"Jansz TT, Noordzij M, Kramer A, Laruelle E, Couchoud C, Collart F, et al. Survival of patients treated with extended-hours haemodialysis in Europe: an analysis of the ERA-EDTA Registry. Nephrol Dial Transplant. 2020;35(3):488\u201395.","journal-title":"Nephrol Dial Transplant"},{"key":"3707_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15204945","author":"C Piombino","year":"2023","unstructured":"Piombino C, Oltrecolli M, Tonni E, Pirola M, Matranga R, Baldessari C, et al. De novo metastatic prostate cancer: Are we moving toward a personalized treatment? Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15204945.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"3707_CR23","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41391-022-00560-3","volume":"26","author":"S Roy","year":"2023","unstructured":"Roy S, Sun Y, Wallis CJD, Morgan SC, Grimes S, Malone J, et al. Development and validation of a multivariable prognostic model in de novo metastatic castrate sensitive prostate cancer. Prostate Cancer Prostatic Dis. 2023;26(1):119\u201325.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"1","key":"3707_CR24","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1186\/s12885-025-14294-7","volume":"25","author":"M Boegemann","year":"2025","unstructured":"Boegemann M, Bennamoun M, Dourthe LM, Encarnacion JA, Hegele A, Hellmis E, et al. Final analysis of ArtemisR, a European real-world retrospective study of apalutamide for the treatment of patients with metastatic hormone-sensitive prostate cancer. BMC Cancer. 2025;25(1):1119.","journal-title":"BMC Cancer"},{"key":"3707_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol32030119","author":"JA Encarnacion Navarro","year":"2025","unstructured":"Encarnacion Navarro JA, Morillo Macias V, Borras Calbo M, De la Fuente Munoz I, Lozano Martinez A, Garcia Martinez V, et al. Multicenter real-world study: 432 patients with apalutamide in metastatic hormone-sensitive prostate cancer. Curr Oncol. 2025. https:\/\/doi.org\/10.3390\/curroncol32030119.","journal-title":"Curr Oncol"},{"issue":"27","key":"3707_CR26","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1080\/14796694.2024.2343647","volume":"20","author":"BH Lowentritt","year":"2024","unstructured":"Lowentritt BH, Du S, Rossi C, Muser E, Khilfeh I, Kinkead F, et al. Real-world clinical outcomes among patients with metastatic castration-sensitive prostate cancer initiating apalutamide. Future Oncol. 2024;20(27):2005\u201313.","journal-title":"Future Oncol"},{"key":"3707_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-024-00929-6","author":"BL Maughan","year":"2024","unstructured":"Maughan BL, Liu Y, Mundle S, Wang X, Nematian-Samani M, Karsh LI. Survival outcomes of apalutamide as a starting treatment: impact in real-world patients with metastatic hormone sensitive prostate cancer (OASIS). Prostate Cancer Prostatic Dis. 2024. https:\/\/doi.org\/10.1038\/s41391-024-00929-6.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"1","key":"3707_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-93136-9","volume":"15","author":"M Shiota","year":"2025","unstructured":"Shiota M, Liu Y, Mundle S, Nematian-Samani M, Hwang J, Wang X, et al. The impact of androgen receptor pathway inhibitors as starting treatment in metastatic castration-sensitive prostate cancer on patient outcomes (OASIS Japan). Sci Rep. 2025;15(1):13598.","journal-title":"Sci Rep"},{"key":"3707_CR29","doi-asserted-by":"publisher","first-page":"1608339","DOI":"10.3389\/fphar.2025.1608339","volume":"16","author":"T Hu","year":"2025","unstructured":"Hu T, Zhou F, Zheng Y, Luo B, Zhang Y, Gu C, et al. Efficacy and safety of darolutamide versus abiraterone acetate plus prednisone in combination with ADT for mHSPC: a real-world clinical retrospective study. Front Pharmacol. 2025;16:1608339.","journal-title":"Front Pharmacol"},{"issue":"3","key":"3707_CR30","doi-asserted-by":"publisher","first-page":"433","DOI":"10.21037\/tau-24-96","volume":"13","author":"J Liu","year":"2024","unstructured":"Liu J, Wang S, Yang Y, Wang S, Campobasso D, Tan YG, et al. Real-world retrospective study of prostate-specific antigen and safety assessment with darolutamide plus androgen deprivation therapy for metastasis hormone-sensitive prostate cancer. Transl Androl Urol. 2024;13(3):433\u201341.","journal-title":"Transl Androl Urol"},{"key":"3707_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14020395","author":"O Baris","year":"2025","unstructured":"Baris O, Oksuzler Kizilbay G, Holat CM, Uzturk ME, Canikoglu M, Durmaz A, et al. The efficacy of the Charlson comorbidity index and its age-adjusted version in forecasting mortality and postoperative outcomes following isolated coronary artery bypass grafting. J Clin Med. 2025. https:\/\/doi.org\/10.3390\/jcm14020395.","journal-title":"J Clin Med"},{"issue":"3","key":"3707_CR32","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1093\/eurpub\/cku238","volume":"25","author":"MC Johnston","year":"2015","unstructured":"Johnston MC, Marks A, Crilly MA, Prescott GJ, Robertson LM, Black C. Charlson index scores from administrative data and case-note review compared favourably in a renal disease cohort. Eur J Public Health. 2015;25(3):391\u20136.","journal-title":"Eur J Public Health"},{"issue":"2","key":"3707_CR33","doi-asserted-by":"publisher","first-page":"41","DOI":"10.36469\/jheor.2025.141170","volume":"12","author":"S Du","year":"2025","unstructured":"Du S, Rossi C, Khilfeh I, Boonmak P, Wong G, Pilon D, et al. Prostate-specific antigen reduction after androgen receptor pathway inhibitor initiation: real-world comparison of disease progression among patients with metastatic castration-sensitive prostate cancer. J Health Econ Outcomes Res. 2025;12(2):41\u20139.","journal-title":"J Health Econ Outcomes Res"},{"key":"3707_CR34","doi-asserted-by":"crossref","unstructured":"Maughan B, Liu Y, Mundle S, Wang X, Karsh L, editors. Rapid and deep prostate-specific antigen (PSA) response to apalutamide plus ADT correlates with improved survival in metastatic castration-sensitive prostate cancer (mCSPC) in real world practice in the US (OASIS Project). American Society of Clinical Oncology Annual Meeting; 2024; Chicago, IL USA.","DOI":"10.1200\/JCO.2024.42.16_suppl.5076"},{"issue":"2","key":"3707_CR35","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.euo.2024.11.005","volume":"8","author":"M Santoni","year":"2025","unstructured":"Santoni M, Buttner T, Rescigno P, Fiala O, Cavasin N, Basso U, et al. Apalutamide in metastatic castration-sensitive prostate cancer: results from the multicenter real-world ARON-3 study. Eur Urol Oncol. 2025;8(2):444\u201351.","journal-title":"Eur Urol Oncol"},{"issue":"2","key":"3707_CR36","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.euo.2024.08.007","volume":"8","author":"M Wenzel","year":"2025","unstructured":"Wenzel M, Cano Garcia C, Humke C, Hoeh B, Steuber T, Tilki D, et al. Prostate-specific antigen nadir and cancer-control outcomes in real-world apalutamide-treated metastatic hormone-sensitive prostate cancer patients: a single-center analysis. Eur Urol Oncol. 2025;8(2):364\u201371.","journal-title":"Eur Urol Oncol"},{"issue":"2","key":"3707_CR37","doi-asserted-by":"publisher","first-page":"231","DOI":"10.2217\/fon-2021-0992","volume":"18","author":"D Pilon","year":"2022","unstructured":"Pilon D, LaMori J, Rossi C, Durkin M, Ghelerter I, Ke X, et al. Medication adherence among patients with advanced prostate cancer using oral therapies. Future Oncol. 2022;18(2):231\u201343.","journal-title":"Future Oncol"},{"key":"3707_CR38","doi-asserted-by":"crossref","unstructured":"Johnson and Johnson. Erleada\u2014highlights of prescribing information. 2026. https:\/\/www.jnjlabels.com\/package-insert\/product-monograph\/prescribing-information\/ERLEADA-pi.pdf.","DOI":"10.1007\/978-3-032-19150-2_6"},{"key":"3707_CR39","unstructured":"Bayer Healthcare. Nubeqa\u2014highlights of prescribing information. 2026. https:\/\/labeling.bayerhealthcare.com\/html\/products\/pi\/Nubeqa_PI.pdf."},{"issue":"5","key":"3707_CR40","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1097\/UPJ.0000000000000841","volume":"12","author":"B Lowentritt","year":"2025","unstructured":"Lowentritt B, Appukkuttan S, Lazarou N, O\u2019Donnell L, Eller J, Grant K, et al. Use of doublet or triplet therapy in metastatic hormone-sensitive prostate cancer across community-based urology settings in the United States. Urol Pract. 2025;12(5):533\u201340.","journal-title":"Urol Pract"},{"key":"3707_CR41","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Prostate Cancer V.5.2026. \u00a9 National Comprehensive Cancer Network, Inc. 2026. All rights reserved. Accessed February 13, 2026. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03707-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03707-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03707-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T15:39:31Z","timestamp":1790609971000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03707-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":41,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["3707"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03707-z","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]},"assertion":[{"value":"13 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Mehmet A. Bilen is an employee of Winship Cancer Institute of Emory University and has received consulting fees from Johnson & Johnson. Gordon Brown is an employee of New Jersey Urology and has received consulting fees from Johnson & Johnson. Mukul Singhal and Courtney D. Longfield are employees and stockholders of Johnson & Johnson. Carmine Rossi and Dominic Pilon are employees of Analysis Group, Inc., a consulting company that has provided paid consulting services to Johnson & Johnson, which funded the development and conduct of this study and manuscript. Benjamin Lowentritt is an employee of Chesapeake Urology and has received consulting fees from Johnson & Johnson.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was considered exempt research under 45 CFR \u00a7 46.104(d)(4) as it involved only the secondary use of data that were de-identified in compliance with the Health Insurance Portability and Accountability Act (HIPAA), specifically, 45 CFR \u00a7 164.514. The study was performed in accordance with the Declaration of Helsinki of 1964 and its later amendments.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}